![Andrew Young](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Andrew Young
Fondateur chez Phoundry Pharmaceuticals, Inc.
Postes actifs de Andrew Young
Sociétés | Poste | Début | Fin |
---|---|---|---|
Phoundry Pharmaceuticals, Inc.
![]() Phoundry Pharmaceuticals, Inc. BiotechnologyHealth Technology Phoundry Pharmaceuticals, Inc. engages in the discovery of peptide therapeutic drugs for metabolic diseases. The firm also provides drugs for diabetes and obesity diseases. The company was founded by Paul L. Feldman, Andrew Young, Ved Srivastava, Mark Paulik, James Way and Shane Roller in 2015 and is headquartered in Research Triangle Park, NC. | Directeur/Membre du Conseil | 01/01/2015 | - |
Directeur Technique/Scientifique/R&D | 01/01/2015 | - | |
Fondateur | 01/01/2015 | - |
Historique de carrière de Andrew Young
Anciens postes connus de Andrew Young
Sociétés | Poste | Début | Fin |
---|---|---|---|
National Institutes of Health
![]() National Institutes of Health General GovernmentGovernment National Institutes Of Health conducts & supports peer-reviewed medical research and science. The firm's scientists & researchers investigate on different ways to prevent diseases as well as the causes, treatments and cures for common and rare diseases. The company was founded in 1887 and is headquartered in Bethesda, MD. | Directeur Technique/Scientifique/R&D | 01/01/1984 | 01/01/1987 |
Satiogen Pharmaceuticals, Inc.
![]() Satiogen Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Satiogen Pharmaceuticals, Inc. engages in the development of therapeutic treatments for diabetes and obesity. It offers a metabolic mechanism for treating diabetes and obesity without intervention by systemically absorbed pharmaceuticals or invasive surgical methods. The firm’s product strategies include non-absorbed ASBT inhibitor, non-surgical biliary shunt, rectal satiogen, non-absorbed TGR5 ligand and labile bile acid sequestrant. The company was founded by Andrew Young and Bronislava Gedulin in 2007 and is headquartered in Del Mar, CA. | Fondateur | 01/01/2007 | - |
Auckland University | Corporate Officer/Principal | - | - |
Amylin Pharmaceuticals, Inc.
![]() Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA. | Directeur Technique/Scientifique/R&D | 01/01/1989 | - |
Formation de Andrew Young
Auckland University | Doctorate Degree |
Statistiques
Internationale
Etats-Unis | 5 |
Nouvelle-Zélande | 2 |
Opérationnelle
Chief Tech/Sci/R&D Officer | 3 |
Founder | 2 |
Corporate Officer/Principal | 1 |
Sectorielle
Health Technology | 3 |
Consumer Services | 2 |
Government | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 4 |
---|---|
Amylin Pharmaceuticals, Inc.
![]() Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA. | Health Technology |
National Institutes of Health
![]() National Institutes of Health General GovernmentGovernment National Institutes Of Health conducts & supports peer-reviewed medical research and science. The firm's scientists & researchers investigate on different ways to prevent diseases as well as the causes, treatments and cures for common and rare diseases. The company was founded in 1887 and is headquartered in Bethesda, MD. | Government |
Satiogen Pharmaceuticals, Inc.
![]() Satiogen Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Satiogen Pharmaceuticals, Inc. engages in the development of therapeutic treatments for diabetes and obesity. It offers a metabolic mechanism for treating diabetes and obesity without intervention by systemically absorbed pharmaceuticals or invasive surgical methods. The firm’s product strategies include non-absorbed ASBT inhibitor, non-surgical biliary shunt, rectal satiogen, non-absorbed TGR5 ligand and labile bile acid sequestrant. The company was founded by Andrew Young and Bronislava Gedulin in 2007 and is headquartered in Del Mar, CA. | Commercial Services |
Phoundry Pharmaceuticals, Inc.
![]() Phoundry Pharmaceuticals, Inc. BiotechnologyHealth Technology Phoundry Pharmaceuticals, Inc. engages in the discovery of peptide therapeutic drugs for metabolic diseases. The firm also provides drugs for diabetes and obesity diseases. The company was founded by Paul L. Feldman, Andrew Young, Ved Srivastava, Mark Paulik, James Way and Shane Roller in 2015 and is headquartered in Research Triangle Park, NC. | Health Technology |
- Bourse
- Insiders
- Andrew Young
- Expérience